Evolution of the Average Target: Grace Therapeutics, Inc.

Evolution of the Target Price: Grace Therapeutics, Inc.

Changes in Analyst Recommendations: Grace Therapeutics, Inc.

6.wPVgjrC8z3_cvv8jS3dnrJRy9EbH8W7lWAtSqkTwTBI.iqQF9PProjaM_Y9VG0It9uUTmDyrugOwMkMGnHGID32Ip1PU24j4Kqj5tg~388890c045ef675002072f93e18da1fe

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- +143.45%
+16.09%
+20.2%
+70.44%
+33.43%
+24.3%
+24.87%
-17.71%
-10.84%
+6.03%
Average +31.03%
Weighted average by Cap. +21.13%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.464CAD
Average target price
8.447CAD
Spread / Average Target
+143.84%
High Price Target
11.22CAD
Spread / Highest target
+223.98%
Low Price Target
5.671CAD
Spread / Lowest Target
+63.71%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

TD Cowen
Craig-Hallum
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.464CAD
Average target price
8.447CAD
Spread / Average Target
+143.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock
  4. Consensus Grace Therapeutics, Inc.